TMPRSS2, a novel host-directed drug target against SARS-CoV-2

Christian Keller1, Eva Böttcher-Friebertshäuser1 and Michael Lohoff2

In a recent study in Nature,1 Shapira et al. reported that the peptidomimetic compound N-0385 inhibited SARS-CoV-2 infection in vitro in remarkably low concentrations by blocking the host cell protease TMPRSS2, which mediates proteolytic cleavage of the SARS-CoV-2 major surface glycoprotein spike (S). Accordingly, N-0385 protected experimentally infected mice from severe SARS-CoV-2 pathology.1

The combat against COVID-19 still largely relies on vaccination against SARS-CoV-2. Yet, some people cannot be vaccinated or mount low or no responses against the vaccine, e.g., elderly people above the age of 80.1 Antigenic escape by, e.g., the Omicron variant (B.1.1.529) may jeopardize passive immunization by monoclonal antibodies, calling for complementary concepts in prophylaxis and therapy. So far, these have concentrated on agents that directly interfere with viral replication, e.g., by inhibition of the viral 3CLpro protease (paxlovid), by inhibition of the RNA-dependent RNA polymerase (remdesivir), or by introducing copying errors (molnupiravir).

Shapira et al. have now demonstrated that it is possible to therapeutically exploit a host cell process that is pivotal in SARS-CoV-2 infection.1 Viral infection not only requires binding of S to its receptor angiotensin-converting enzyme 2 (ACE2) but also cleavage of S at two distinct sites by host cell proteases: First, furin (and related pro-protein convertases) cleaves at a polybasic site, generating the S1 and S2 subunits, which remain non-covalently linked (S1/S2 site, Fig. 1a). Upon receptor binding, another cleavage site (S2’ site) located immediately upstream of the hydrophobic fusion peptide, is exposed, and a second cleavage is mediated by TMPRSS2 and related proteases (Fig. 1a). This enables exposure of the fusion machinery located in the S2 subunit.7 Previous work by Bestle et al. had indicated that synergistic inhibition of furin by the peptidomimetic inhibitor MI-1851 and TMPRSS2 by MI-432 or MI-1900 in micromolar concentrations significantly reduced viral replication in vitro.1 Shapira et al. now added to this work by demonstrating that inhibition of TMPRSS2 by peptidomimetic tetrapeptide compounds with ketobenzothiazole warheads is effective against SARS-CoV-2 even in nanomolar concentrations.1 Mechanistically, TMPRSS2 inhibition results in incompletely cleaved, fusion-incompetent SARS-CoV-2 viruses that are unable to infect new host cells (Fig. 1a).

From eight candidates, the authors identified N-0385 as the most potent inhibitor of TMPRSS2 and viral infection in vitro. Its antiviral action was verified in human intestinal biopsy-derived colonoids, a recently developed primary cell system. With a selectivity index of >104, inhibition was highly specific for TMPRSS2. Importantly, the authors demonstrated the antiviral activity of N-0385 against four variants of concern (Alpha, Beta, P1, and Delta).

For in vivo studies, the authors continued in a humanized K18-hACE2 mouse model, in which transgenic expression of human ACE2 is controlled by the cytokeratin 18 promoter. Intranasal administration of N-0385 before and during SARS-CoV-2 infection significantly reduced mortality and morbidity.1 Also, a shorter prophylactic treatment with only four administrations (7.2 mg/kg) and initiated before infection, reduced viral titers in the lungs and protected all treated mice from a lethal outcome. Interestingly, even a single treatment with N-0385 (14.4 mg/kg) given 12 h post infection with the Delta variant reduced weight loss and viral titers in the lungs of infected mice.

The data presented by Shapira et al. suggest spike maturation by inhibiting TMPRSS2 as a potent drug target in COVID-19 when the inhibitor is given before or early in infection. Most currently licensed antivirals are applicable in the early phase, until day 5–7 after the onset of symptoms. This requirement to treat early was thus not overcome by the present study, and the therapeutically window of TMPRSS2 inhibition needs to be studied more extensively. A prophylactic application, however, emerges as a realistic scenario. As an improvement to previously described TMPRSS2 inhibitors that required micromolar concentrations, N-0385 acted against SARS-CoV-2 in the nanomolar range and with increased specificity.

The study also revealed some heterogeneity between male and female groups; females appeared either less susceptible to infection or more susceptible to treatment.1 Future studies should therefore address sex differences in antiviral therapy. Synergistic treatments with directly acting antivirals or other protease inhibitors (e.g., aprotinin) will equally be a worthwhile field of study.

As an advantage over virus-directed therapies, host-directed targets have a low potential for resistance: The TMPRSS2 cleavage site of the SARS-CoV-2 spike protein has remained very conserved over the pandemic (Fig. 1b), suggesting that N-0385 should retain a high potency against future variants of concern. Another advantage to target TMPRSS2 is its activating function in other viral infections (e.g., other coronaviruses, influenza virus), which expands the field of potential applications for TMPRSS2 inhibitors. The recently described crystal structure of TMPRSS2 might facilitate further improvements by structure-based drug design (Fig. 1c).

Broad-spectrum serine protease inhibitors against COVID-19 that were recently evaluated in clinical trials are intravenous nafamostat, a synthetic inhibitor, and aerosolized aprotinin, a

1Institute of Virology, Philipps University Marburg, Marburg, Germany
2Institute of Medical Microbiology and Hygiene, Philipps University Marburg, Marburg, Germany

Correspondence: Christian Keller (christian.keller@staff.uni-marburg.de)

Received: 10 May 2022 Revised: 23 June 2022 Accepted: 26 June 2022
Published online: 23 July 2022
protease inhibitor from bovine lung. For nafamostat, one study demonstrated a small effect with respect to recovery rate and mortality in high-risk COVID-19 patients requiring oxygen treatment.4 Adverse effects, which may restrict its use as an intravenous drug, included catheter site phlebitis, hyponatremia, and respiratory failure.4 More encouraging data came from the aprotinin study: aerosolized aprotinin reduced the length of hospital admission and oxygen requirement.5 Importantly, no adverse reactions were observed. Thus, inhalation could be a safer way to administer protease inhibitors against COVID-19, tailored to reach TMPRSS2 that is expressed on the cell surface of target cells in the airways. While the physiological role of TMPRSS2 in humans is not clear, it is non-essential in mice. Since redundant proteases should take over its function, inhibition with selective compounds is likely not to produce relevant side effects.

Taken together, Shapira et al. have developed a potent TMPRSS2 inhibitor and provided robust evidence that host-directed inhibition of TMPRSS2 by the peptidomimetic compound N-0385, thus preventing spike maturation, is effective against SARS-CoV-2 in vitro and in vivo, including variants of concern. People without vaccination, with poor vaccine responses or with an increased risk for severe infection courses are likely to benefit most from TMPRSS2 inhibition, which at this stage ought to be initiated soon after exposure.

ACKNOWLEDGEMENTS
We thank Dorothea Bestle and Torsten Steinmetzer for help in creating the figures.

FUNDING
Open Access funding enabled and organized by Projekt DEAL.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

REFERENCES
1. Shapira, T. et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature 605, 340–348 (2022).
2. Romero-Olmedo, A. J. et al. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. Nat. Microbiol. 7, 195–199 (2022).
3. Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance 3, 1–14 (2020).
4. Zhuravel, S. V. et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomized phase II clinical trial. eClinicalMedicine 41, 101169 (2021).
5. Redondo-Calvo, F. J. et al. Aprotinin treatment against SARS-CoV-2: a randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. Eur. J. Clin. Investig. 52, e13776 (2022).
